Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Periostin on the road to nonalcoholic fatty liver disease.

Literature DB >> 26585566

Periostin on the road to nonalcoholic fatty liver disease.

Stergios A Polyzos¹, Athanasios D Anastasilakis².

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2015 PMID： 26585566 DOI： 10.1007/s12020-015-0803-7

Source DB: PubMed Journal: Endocrine ISSN： 1355-008X Impact factor: 3.633

× No keyword cloud information.

14 in total

Review 1. Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease.

Authors: Stergios A Polyzos; Jannis Kountouras; Christos Zavos; Georgia Deretzi
Journal: J Clin Gastroenterol Date: 2012-04 Impact factor: 3.062

2. Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease.

Authors: Stergios A Polyzos; Christos S Mantzoros
Journal: Metabolism Date: 2013-10-28 Impact factor: 8.694

3. Deficiency of periostin protects mice against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis.

Authors: Yuan Li; Shasha Wu; Shanshan Xiong; Gaoliang Ouyang
Journal: J Hepatol Date: 2014-10-13 Impact factor: 25.083

4. Matricellular protein periostin contributes to hepatic inflammation and fibrosis.

Authors: Yangmei Huang; Weiping Liu; Hongjun Xiao; Alaiyi Maitikabili; Qinghua Lin; Tiantian Wu; Zhengjie Huang; Fan Liu; Qi Luo; Gaoliang Ouyang
Journal: Am J Pathol Date: 2014-12-23 Impact factor: 4.307

Review 5. Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments.

Authors: Allan Yi Liu; Hong Zheng; Gaoliang Ouyang
Journal: Matrix Biol Date: 2014-05-09 Impact factor: 11.583

Review 6. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines.

Authors: Stergios A Polyzos; Jannis Kountouras; Christos Zavos
Journal: Curr Mol Med Date: 2009-04 Impact factor: 2.222

7. Serum periostin is a potential biomarker for non-alcoholic fatty liver disease: a case-control study.

Authors: Jin-Zhou Zhu; Hua-Tuo Zhu; Yi-Ning Dai; Chun-Xiao Li; Zhi-Yun Fang; De-Jian Zhao; Xing-Yong Wan; Yu-Ming Wang; Fang Wang; Chao-Hui Yu; You-Ming Li
Journal: Endocrine Date: 2015-09-11 Impact factor: 3.633

8. Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα.

Authors: Yan Lu; Xing Liu; Yang Jiao; Xuelian Xiong; E Wang; Xiaolin Wang; Zhijian Zhang; Huijie Zhang; Lingling Pan; Youfei Guan; Dongsheng Cai; Guang Ning; Xiaoying Li
Journal: J Clin Invest Date: 2014-07-08 Impact factor: 14.808

9. High preoparative levels of serum periostin are associated with poor prognosis in patients with hepatocellular carcinoma after hepatectomy.

Authors: Y Lv; W Wang; W D Jia; Q K Sun; M Huang; H C Zhou; H H Xia; W B Liu; H Chen; S N Sun; G L Xu
Journal: Eur J Surg Oncol Date: 2013-07-31 Impact factor: 4.424